This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Andrew Tepperman prepared an expert statement on behalf of Respondent in an ICC dispute concerning allegedly underpaid royalties.
He opined on economic and industry norms in pharmaceutical patent license agreements, focusing on provisions that may result in deductions from the base of sales on which royalties are paid, as well as the term of the royalty obligation.
Dear Clients and Friends, Our activities in 2024 reflected ongoing trends from 2023 and emerging forces affecting the landscape for investors and companies...
2023 marked a significant surge in activity across diverse sectors such as mining, oil & gas, the energy transition, pharma, and merger disputes. Throughout...
